MedPage Today1h
FDA Investigating Blood Cancer Risk With Gene Therapy Skysona
The FDA said on Wednesday that it is investigating reports of blood cancers -- including life-threatening cases of ...
FDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory action
The U.S. Food and Drug Administration is weighing the need for a regulatory action on bluebird bio's gene therapy for a rare ...
Soup Recall Update as FDA Sets Highest Risk Level
A soup mix recall issued this month has been updated by the U.S. Food and Drug Administration ( FDA) as a Class I risk, the ...
Seafood Recall Update As FDA Sets Risk Level
The seafood salad may be of particular risk to those customers who have an allergy or severe sensitivity to soy, the FDA has ...
Vivek Ramaswamy’s crusade to change FDA could boost biotech, and himself
The co-leader of President-elect Donald Trump’s initiative to cut government spending has a financial stake in the biotech ...
Exclusive: Thousands turn to Wegovy copies each month as FDA considers shortage status
More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...
Healthy Returns: Trump's FDA pick Makary may be a relief for biotech and pharma, analysts say
Trump’s FDA pick, Marty Makary, appears to be quelling fears about a major disruption to biotech and pharma. Neuralink ...
Popular asthma drug Singulair could be linked to mental health side effects, suicides: FDA
Singulair, a popular asthma medication, could be linked to severe side effects, including suicide, a study from the FDA found ...
FDA says it found bacteria, ‘mold-like’ substances in this popular toothpaste
Federal officials said they found black mold and disease-causing bacteria in a popular brand of toothpaste. In a letter dated ...
Meet Trump’s picks for CDC, FDA
Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump picks heads of CDC, FDA and ...
Biden COVID response coordinator: Trump picks for FDA, NIH ‘pretty reasonable’
Ashish Jha, the dean of the Brown University School of Public Health and former White House coronavirus coordinator under ...
FierceBiotech8h
Outlook's stock plummets after eye drug fails to match Lucentis, but biotech still plans FDA filing
Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...